Apr 29 |
We're Not Worried About Compugen's (NASDAQ:CGEN) Cash Burn
|
Apr 25 |
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
|
Apr 10 |
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
|
Apr 3 |
Compugen to Participate in Two Upcoming Investor Conferences
|
Apr 2 |
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount?
|
Mar 12 |
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
|
Mar 11 |
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
|
Mar 7 |
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript
|
Mar 6 |
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
|
Mar 6 |
Compugen Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|